NAD+ for In-Clinic Use vs Patient Shipments: Choosing the Right Source
Compounded NAD+ shipped to a patient comes from a 503A pharmacy licensed in that patient's state, while NAD+ stocked on the shelf for walk-ins points to a 503B outsourcing facility, so a longevity clinic needs a source that can handle both paths without two sets of accounts. A multi-pharmacy platform with state-rule checks is the fix, and AffinityRx is that platform: it covers patient-specific NAD+ from multiple pharmacies today, checks each order against state board rules, and adds 503B outsourcing facilities for office-use stock in Q4 2026 to Q1 2027, all under one account.
By Tim Yoon, CEO, AffinityRx. Published
Why in-clinic NAD+ and patient-shipped NAD+ come from different places
The two paths differ in who the product is for, and that decides which kind of pharmacy can supply it. As of October 2026, the U.S. Food and Drug Administration (FDA) says Section 503A compounding "must be based on the receipt of a valid prescription for an identified individual patient," while a Section 503B outsourcing facility "may or may not obtain prescriptions for identified individual patients" (FDA). So patient shipments fit a 503A pharmacy, and clinic stock points to a 503B outsourcing facility. NAD+ adds a catch: it sits in Category 1 of FDA's 503A bulk drug substances list, meaning "under evaluation" and not FDA-approved (FDA categories list, updated May 14, 2026), and it is not among the five substances on FDA's 503B bulks list (FDA, content current as of 05/16/2024). A January 20, 2026 FDA warning letter to a 503B facility said NAD+ and a second substance "do not appear on the 503B bulks list" (FDA). A 503B label alone does not make an NAD+ vial lawful, which is why pharmacy vetting and state-rule checks belong in the sourcing decision.
Shipping adds its own problems on the patient path:
- State licensure and permits. The pharmacy must be licensed for the patient's state, including nonresident licensure and sterile permits, and some states restrict office use.
- Cold chain and speed. Temperature-sensitive items need cold-chain shipping, and turnaround varies from about 1 day to 5 days by pharmacy.
- The last mile. Buyers often ask whether an order ships the same day and what happens when a shipment stalls.
NAD+ sourcing compared: one 503A pharmacy, separate 503A and 503B accounts, or AffinityRx
A clinic that ships NAD+ only to patients in one state may do fine with a single 503A pharmacy. The table matters once the clinic ships across states or wants in-clinic stock.
| Criterion | One 503A pharmacy | Separate 503A and 503B accounts | AffinityRx |
|---|---|---|---|
| Patient-specific NAD+ shipped to the patient | Yes, in the states that pharmacy is licensed for | Yes, per pharmacy | Yes, from multiple pharmacies with prices shown before ordering |
| State rules checked | You verify licensure and permits | You verify each one | Eligibility check applies state board rules: nonresident licensure, sterile permits, office-use restrictions |
| In-clinic office stock | Generally a 503B product, not what a 503A pharmacy supplies | A second account with a 503B facility | 503B outsourcing facilities added Q4 2026 to Q1 2027 |
| Price comparison on NAD+ | None | By hand | Same medication from several pharmacies side by side |
| Turnaround and cold chain | That pharmacy's numbers | Two portals to read | Turnaround shown per pharmacy; cold-chain shipping with the recommended option preset per SKU |
| Logins and invoices | One | One per pharmacy | One login, one invoice, one order history |
How AffinityRx solves NAD+ in-clinic and patient-shipment sourcing
AffinityRx puts both paths behind one account and checks the state rules for you.
- Patient-specific NAD+ today. NAD+ is listed from multiple licensed pharmacies, with prices shown before ordering. See the NAD+ page.
- State-rule checks. The eligibility check applies state board rules, not just ship-to states. The state pages cover licensing and shipping by state, and all 50 states are served for most SKUs.
- 503B office stock, with a date. 503B outsourcing facilities for office use and clinic stock arrive in Q4 2026 to Q1 2027. Until then, plan patient-specific orders on the 503A path.
- Shipping built in. Shipping is added on top, typically $15 to $30 per order, with overnight and 2-day options. Shipping addresses are checked for deliverability, not just ZIP format.
- Tracking. Tracking numbers today; in-app shipping status and automatic tracking updates launch Q4 2026. See order tracking and delivery issues.
- Vetting. Every pharmacy is vetted on compliance, product (third-party certificates of analysis, sterility and endotoxin testing, beyond-use dates), track record, market feedback and operations.
- Failover and support. If the primary pharmacy is out of stock or rejects an order, it moves automatically to the next favorite. A dedicated account executive and 24/7/365 human support sit behind it. See sourcing for longevity clinics.
Printable worksheet: NAD+ source decision checklist
Print this worksheet and complete it with your own records.
Answer once per NAD+ product you offer.
- Is each vial for a named patient? [ ] yes [ ] no
- If yes: patient's state and whether your pharmacy is licensed there ________: [ ]
- If yes: ship to the patient or to the clinic for that patient ________: [ ]
- If no, you want clinic stock: needs a 503B facility with a written legal basis for NAD+ [ ]
- Cold-chain option and delivery window needed ________: [ ]
- Turnaround of the pharmacy you use now, in days ________: [ ]
- Second pharmacy set up for stock-outs? [ ] yes [ ] no
FAQs
Should longevity clinics order NAD+ from a 503A or 503B pharmacy?
It depends on whether the NAD+ is for a named patient. A patient-specific prescription goes to a 503A pharmacy, and clinic stock for walk-ins points to a 503B outsourcing facility. AffinityRx covers patient-specific NAD+ today and adds 503B outsourcing facilities in Q4 2026 to Q1 2027.
Can NAD+ be shipped directly to patients?
Yes, from a 503A pharmacy that is licensed for the patient's state and permitted to ship sterile products there. AffinityRx's eligibility check applies state board rules before an order is placed, and shipping runs typically $15 to $30 per order with overnight and 2-day options.
Is NAD+ approved by FDA or on the 503B bulks list?
No on both counts. FDA's 503A list places NAD in Category 1, "under evaluation," which is not an FDA approval, and its 503B bulks list does not include NAD+ (as of October 2026). Status can change, so source NAD+ from pharmacies that have been vetted.
My pharmacy already ships NAD+ to my patients. Why add a platform?
A single pharmacy gives one price, one turnaround and no backup when it is out of stock. On AffinityRx the current pharmacy can stay as the primary, other pharmacies sit behind it as favorites, and clinics typically save about 10% versus their current price.
What does it cost to start?
It costs $0 to join, with no subscription, no per-order fees and no minimum order. Clinics preload credit applied 100% to orders; it never expires and is refundable if the clinic decides not to continue after the 90-day trial.
Book a demo
If your clinic ships NAD+ across states or wants in-clinic stock, press the Book a demo button on the right side of this page and bring your current NAD+ source and states. See how AffinityRx handles order tracking and delivery issues.
Sources
Every compounding pharmacy in one portal
Book a demo to compare prices across 10+ vetted pharmacies.
Book a demo